Incyte Blood Cancer Drug Combo Reduces Disease-Progression Risk but With High Side-Effect Rate
May 30 (Reuters) – Incyte’s Monjuvi as part of a multi-drug regimen that includes a chemotherapy standard of care for an aggressive form of non-Hodgkin lymphoma reduced the risk of disease progression, relapse or death by 25% compared to the standard alone, but with a higher rate of study dropouts due to side effects. The …